{"groups":[{"description":"Idelalisib 150 mg tablet administered orally twice daily until tumor progression or development of unacceptable toxicity.","id":"FG000","title":"Idelalisib"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"30"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"6"}],"type":"Withdrew Consent"},{"reasons":[{"groupId":"FG000","numSubjects":"7"}],"type":"Investigator Request"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Other (Unknown)"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"125"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"70"}],"type":"Completed: Disease Progression"},{"achievements":[{"groupId":"FG000","numSubjects":"9"}],"type":"Completed: Death"},{"achievements":[{"groupId":"FG000","numSubjects":"79"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"46"}],"type":"NOT COMPLETED"}],"title":"Treatment Period (TP) (81 Months)"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Withdrew Consent"},{"reasons":[{"groupId":"FG000","numSubjects":"40"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"21"}],"type":"Other (Unknown)"}],"milestones":[{"achievements":[{"comment":"Participants did not have to complete the TP in order to enter the Long-term Follow-up Period.","groupId":"FG000","numSubjects":"84"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"20"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"64"}],"type":"NOT COMPLETED"}],"title":"Long-term Follow-up Period (5 Years)"}],"preAssignmentDetails":"125 participants were enrolled and treated and comprise the Intent-to-Treat (ITT) Analysis Set.","recruitmentDetails":"Participants were enrolled at a total of 54 study sites in North America and Europe. The first participant was screened on 04 March 2011. The last participant observation was on 16 May 2018."}